| 1 | Anti-von Willebrand Factor Nanobody, Caplacizumab | [1] Caplacizumab Caplacizumab (Caplacizumab) | [1] Caplacizumab
Caplacizumab
(Caplacizumab, Caplacizumab-yhdp) 💬
| [1] VWF VWF 💬
| [9] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
| 2 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab | [1] Caplacizumab Caplacizumab (Caplacizumab) | [1] Caplacizumab
Caplacizumab
(Caplacizumab, Caplacizumab-yhdp) 💬
| [1] VWF VWF 💬
| [9] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
| 3 | Cablivi®Product Name: Cablivi®Product Code: ALX0081Pharmaceutical Form: Powder and solvent for solution for injectionINN or Proposed INN: CaplacizumabCAS Number: 915810-67-2Current Sponsor code: ALX0081Other descriptive name: Nanobody directed towards the human A1 domain of von Willebrand factorConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 12.5-Trade Name: Cablivi®Product Name: Cablivi®Product Code: ALX0081Pharmaceutical Form: Powder and solvent for solution for injectionINN or Proposed INN: CaplacizumabCAS Number: 915810-67-2Current Sponsor code: ALX0081Other descriptive name: Nanobody directed towards the human A1 domain of von Willebrand factorConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 12.5- | - | - | - | - | [1] 64 64 💬
|
| 4 | Caplacizumab | [1] Caplacizumab Caplacizumab (Caplacizumab) | [1] Caplacizumab
Caplacizumab
(Caplacizumab, Caplacizumab-yhdp) 💬
| [1] VWF VWF 💬
| [9] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [2] 63 63, 64 💬
|
| 5 | Caplacizumab (ALX-0081) | [1] Caplacizumab Caplacizumab (Caplacizumab) | [1] Caplacizumab
Caplacizumab
(Caplacizumab, Caplacizumab-yhdp) 💬
| [1] VWF VWF 💬
| [9] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
| 6 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | [1] Caplacizumab Caplacizumab (Caplacizumab) | [1] Caplacizumab
Caplacizumab
(Caplacizumab, Caplacizumab-yhdp) 💬
| [1] VWF VWF 💬
| [9] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
| 7 | Caplacizumab (an anti-von Willebrand Factor Nanobody) | [1] Caplacizumab Caplacizumab (Caplacizumab) | [1] Caplacizumab
Caplacizumab
(Caplacizumab, Caplacizumab-yhdp) 💬
| [1] VWF VWF 💬
| [9] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Integrin signaling, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|